Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/11/21
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine DiseasesGlobeNewsWire • 03/10/21
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10GlobeNewsWire • 03/04/21
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021GlobeNewsWire • 02/26/21
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewsWire • 02/18/21
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences TeamBusiness Wire • 01/26/21
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/11/21
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/21
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical ProgramGlobeNewsWire • 12/30/20
Implied Volatility Surging for Ascendis Pharma (ASND) Stock OptionsZacks Investment Research • 12/30/20
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual ConferenceGlobeNewsWire • 11/25/20
Ascendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare DiseasesGlobeNewsWire • 11/03/20
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11GlobeNewsWire • 11/02/20
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in EuropeGlobeNewsWire • 10/23/20